Revolutionizing Cancer Care at UHN: A unique gamma delta TCR as a novel cancer therapeutic approach скачать в хорошем качестве

Revolutionizing Cancer Care at UHN: A unique gamma delta TCR as a novel cancer therapeutic approach

A powerful new frontier in cancer immunotherapy is emerging at UHN. Dr. Pam Ohashi, Senior Scientist and Director of the Tumour Immunotherapy Program at UHN’s Princess Margaret Cancer Centre, and her team have identified a new T-cell receptor that may be used for cancer immunotherapy. This approach uses a unique gamma delta T-cell receptor (TCR) to reprogram immune cells with greater precision and safety than current treatments, such as CAR-T. Its clinical potential is still being explored. Supported by promising early research, this next-generation treatment platform is poised to expand the reach and impact of immune-based cancer therapies. We are actively seeking licensing partners and co-development opportunities to bring this technology to patients worldwide. For partnering inquiries, please contact commercialization@uhn.ca.